$CBIO Recent Highlights and Upcoming Milestones
Recent Highlights:
Catalyst Biosciences’ Factor IX Recommended for Orphan Drug Designation in Europe
Contract revenue for the three months ended March 31, 2017 was $0.3 million, compared with $0.1 million for the prior year period. The increase in contract revenue was due to the milestone revenue from ISU Abxis of $0.2 million.
Cash, cash equivalents and short-term investments as of March 31, 2017 were $14.5 million
The Company believes that its existing capital resources will be sufficient to meet its projected operating requirements for at least the next 12 months.
Raised $20.7 million through an underwritten public equity offering that included the full exercise of the underwriters’ over-allotment option to purchase additional shares and warrants on April 12, 2017
Achieved key milestones with CB 2679d/ISU304, the Company’s next-generation coagulation Factor IX, as follows:
Investigational New Drug (IND) application approved by the Korean Ministry of Food and Drug Safety (MFDS)
Completion of IND-enabling toxicology studies triggered a milestone payment from Catalyst’s collaboration partner, ISU Abxis
Advanced the development of marzeptacog alfa (activated), the Company’s next-generation Factor VIIa, including the following accomplishments:
Received notice from the European Patent Office that the opposition period, for a patent granted to Catalyst, has expired and no opposition has been filed
Selected a global contract research organization, INC Research, to conduct the Phase 2/3 efficacy clinical trial of marzeptacog alfa (activated) in individuals with hemophilia A or B with an inhibitor
Anticipated Milestones
CB 2679d/ISU304: Initiate a Phase 1/2 proof-of-concept clinical trial in individuals with severe hemophilia B in the second quarter of 2017; the trial will be conducted by Catalyst’s collaborator, ISU Abxis (KOSDAQ: 086890) in South Korea
Marzeptacog alfa (activated): Initiate the Phase 2 part of a Phase 2/3 efficacy clinical trial in individuals with hemophilia A or B with an inhibitor in the fourth quarter of 2017
Recent Highlights:
Catalyst Biosciences’ Factor IX Recommended for Orphan Drug Designation in Europe
Contract revenue for the three months ended March 31, 2017 was $0.3 million, compared with $0.1 million for the prior year period. The increase in contract revenue was due to the milestone revenue from ISU Abxis of $0.2 million.
Cash, cash equivalents and short-term investments as of March 31, 2017 were $14.5 million
The Company believes that its existing capital resources will be sufficient to meet its projected operating requirements for at least the next 12 months.
Raised $20.7 million through an underwritten public equity offering that included the full exercise of the underwriters’ over-allotment option to purchase additional shares and warrants on April 12, 2017
Achieved key milestones with CB 2679d/ISU304, the Company’s next-generation coagulation Factor IX, as follows:
Investigational New Drug (IND) application approved by the Korean Ministry of Food and Drug Safety (MFDS)
Completion of IND-enabling toxicology studies triggered a milestone payment from Catalyst’s collaboration partner, ISU Abxis
Advanced the development of marzeptacog alfa (activated), the Company’s next-generation Factor VIIa, including the following accomplishments:
Received notice from the European Patent Office that the opposition period, for a patent granted to Catalyst, has expired and no opposition has been filed
Selected a global contract research organization, INC Research, to conduct the Phase 2/3 efficacy clinical trial of marzeptacog alfa (activated) in individuals with hemophilia A or B with an inhibitor
Anticipated Milestones
CB 2679d/ISU304: Initiate a Phase 1/2 proof-of-concept clinical trial in individuals with severe hemophilia B in the second quarter of 2017; the trial will be conducted by Catalyst’s collaborator, ISU Abxis (KOSDAQ: 086890) in South Korea
Marzeptacog alfa (activated): Initiate the Phase 2 part of a Phase 2/3 efficacy clinical trial in individuals with hemophilia A or B with an inhibitor in the fourth quarter of 2017